ProstACT Global is trialling a promising new treatment option for prostate cancer, which is the most commonly diagnosed cancer and the second leading cause of cancer-related death for U.S. men. This ...
Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) announces that the Biogenix Molecular Research Center ...
GLP-1 receptor agonists are transforming obesity treatment, but manufacturing challenges must be addressed to meet rising ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback